School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Orchestra BioMed Holdings, Inc. OBIO

Healthcare · Biotechnology

$5.95last close 2026-10-09 · market cap $355.22M · delayed data

Trailing returns

1M+9.17%
3M+51.79%
6M+40.66%
1Y+107.32%
5Y-39.47%

Basis: Adjusted daily closes.

What it does

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease.

Open OBIO in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies